Spotlight on smart lock highlights ways families, senior caregivers can keep those with dementia safe
By
Aaron Dorman
Sep 11, 2023
A smart lock for dementia highlights recent tech aimed at monitoring and keeping senior family members safe.
Panel of 48 CSF proteins complements existing Alzheimer’s biomarkers
Sep 07, 2023
The CSF 48 panel plus existing biomarkers significantly improved the diagnostic performance for the outcomes studied.
Composite inflammatory biomarker linked to dementia risk
Jul 21, 2023
Small but significant associations were seen between elevated biomarker levels and worsened cognitive performance.
Finger prick, venous blood can ID key Alzheimer’s disease biomarkers
Jul 20, 2023
Capillary and venous dry blood spot can identify glial fibrillary acidic protein, neurofilament light and phosphorylated tau.
Smartwatch tool predicts Parkinson’s disease up to 7 years before onset
By
Aaron Dorman
Jul 11, 2023
Data from a smart watch could help predict Parkinson’s disease up to seven years before symptoms begin occurring, a new study shows.
More news for Monday, March 6
By
Kimberly Bonvissuto
Mar 06, 2023
Lifetime experiences of discrimination linked to increased risk of dementia … Obesity linked to 21 genes related to Alzheimer’s disease … Another bill aims to give veterans more long-term care options
Plasma biomarkers identified for detecting presymptomatic Alzheimer’s disease
Jan 13, 2023
Plasma P-tau181, NfL and GFAP concentrations were higher in mutation carriers versus noncarriers of autosomal dominant Alzheimer’s disease.
Lecanemab reduced markers of amyloid in early Alzheimer’s disease
Dec 01, 2022
Moderately less decline was seen in cognition and function at 18 months with lecanemab versus placebo.
Changes in Alzheimer’s biomarkers tied to withdrawal of PAP for OSA
Jul 08, 2022
An increase in neurofilament light and a decrease in Aβ40 were associated with withdrawal of positive airway pressure for obstructive sleep apnea.
FDA OKs marketing of new test to help diagnose Alzheimer disease
May 06, 2022
The test is indicated for patients 55 years and older who present with cognitive impairment and are being evaluated for Alzheimer’s disease and cognitive decline.